MRNA · News · 20260730N

Revenue Performance and Mix

Moderna, Inc. · 2026-07-30 · Importance 69 · Surprise 64

Moderna reported first-quarter 2026 revenue of $389 million, up 260.2% year over year. The company generated $3.0 billion of revenue in 2025, down sharply from pandemic-era levels. Messenger RNA (mRNA) Medicines remained the primary revenue segment, while the United States contributed €1.02 billion of the €1.66 billion reported in the referenced annual revenue breakdown. Analysts expected second-quarter 2026 revenue of approximately $103 million, implying a decline of about 28% year over year, although that estimate was not yet reported company revenue.

Key facts

• Seeking Alpha reports expectations of a $2 per share loss and a 28% decline in revenue to $103M for Q2. source
• Moderna beat revenue and EPS expectations last quarter with 260% year-on-year revenue growth. source
• Analysts are anticipating a 24.8% revenue decline for Moderna this quarter. source